FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Yves Reginster

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Geographic Areas

Belgium

Anatomy

Lumbar Vertebrae

Co-author Network

Publications

TOP 3
Cyrus Cooper; Bruno Flamion; Helgi Jonsson; John A Kanis; Willem F Lems; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Franz Pelousse; Jean-Yves Reginster; Susanne Reiter; René Rizzoli; Jonathan D Adachi; Thomas Bardin; Francis Berenbaum; Olivier Bruyère
How to define responders in osteoarthritis.
Jean-Pierre Devogelaer; Stefan Goemaere; Sophia Ish-Shalom; Philemon Papanastasiou; Christina Bucci-Rechtweg; Julien Collette; David M Reid; Philip Sambrook; Guoqin Su; Jean-Yves Reginster
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Jean-Yves Reginster; Franz Pelousse
Supplementation with vitamin D did not reduce cartilage volume loss or pain in knee osteoarthritis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Yves Reginster (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Cyrus Cooper; Bruno Flamion; Helgi Jonsson; John A Kanis; Willem F Lems; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Franz Pelousse; Jean-Yves Reginster; Susanne Reiter; René Rizzoli; Jonathan D Adachi; Thomas Bardin; Francis Berenbaum; Olivier Bruyère
How to define responders in osteoarthritis.
Current medical research and opinion 2013;29(6):719-29.
2013: Jean-Pierre Devogelaer; Stefan Goemaere; Sophia Ish-Shalom; Philemon Papanastasiou; Christina Bucci-Rechtweg; Julien Collette; David M Reid; Philip Sambrook; Guoqin Su; Jean-Yves Reginster
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Rheumatology (Oxford, England) 2013;52(6):1058-69.
2013: Jean-Yves Reginster; Franz Pelousse
Supplementation with vitamin D did not reduce cartilage volume loss or pain in knee osteoarthritis.
Annals of internal medicine 2013;158(8):JC9.
2013: René Rizzoli; G Weryha; J D Ringe; S Boonen; M-L Brandi; Olivier Bruyère; C Cooper; J A Kanis; J-M Kaufman; Jean-Yves Reginster
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Current medical research and opinion 2013;29(4):305-13.
2013: Mickael Hiligsmann; Wafa Ben Sedrine; Jean-Yves Reginster
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2013;28(4):807-15.
2013: Olivier Bruyère; S Compère; P Jeholet; P Maassen; D Nicolet; Grégory A Pire; Véronique Rabenda; Brigitte Zegels; Jean-Yves Reginster
Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture.
Rheumatology international 2013;33(4):979-83.
2013: Olivier Bruyère; M Fossi; M Hiligsmann; L Leonori; Audrey Neuprez; Brigitte Zegels; Jean-Yves Reginster
Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.
Rheumatology international 2013;33(4):973-8.
2013: Jean-Marc Kaufman; E McCloskey; Bruce H Mitlak; Eric Orwoll; Jean-Yves Reginster; Johann D Ringe; S Boonen; M L Brandi; C Cooper; W Dere; Jean-Pierre Devogelaer; Adolfo Diez-Perez; J A Kanis; G Weryha; R Rizzoli
Treatment of osteoporosis in men.
Bone 2013;53(1):134-44.
2013: Mickaël Hiligsmann; Annelies Boonen; Carmen D Dirksen; Wafa Ben Sedrine; Jean-Yves Reginster
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
Expert review of pharmacoeconomics & outcomes research 2013;13(1):19-28.
2013: Jean-Yves Reginster; Philip N Sambrook; Timothy D Spector; Harry Genant; Evgeny Nasonov; Federico Navarro; Janusz E Badurski; Nicholas Bellamy; William Bensen; Roland Chapurlat; Xavier Chevalier; Claus Christiansen; Cyrus Cooper
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.
Annals of the rheumatic diseases 2013;72(2):179-86.
2013: Charlotte Beaudart; Fanny Buckinx; Jean-Michel Crielaard; Marie Demonceau; Mélanie Mannarino; Didier Maquet; Jean-Yves Reginster; Olivier Bruyère
Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents.
BMC geriatrics 2013;13():42.
2013: Mickael Hiligsmann; Jean-Yves Reginster; Trudy van der Weijden; Caroline van Durme; Benedict Gc Dellaert; Carmen D Dirksen; Piet Geusens; Annelies Boonen
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis.
Patient preference and adherence 2013;7():133-9.
2013: John A Kanis; Eugene McCloskey; Jean-Yves Reginster; René Rizzoli; C Cooper; Helena Johansson
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013;24(1):23-57.
2013: Véronique Rabenda; C Beaudart; Olivier Bruyère; D Nicolet; Jean-Yves Reginster
Relationship between use of antidepressants and risk of fractures: a meta-analysis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013;24(1):121-37.
2012: Steven Boonen; Kim Brixen; Christina Bucci-Rechtweg; Frank Claessens; Hans Peter Dimai; Erik Eriksen; Josef Hruska; Elodie Incera; Jean-Marc Kaufman; Bente Langdahl; Kurt Lippuner; Stanley Lipschitz; Philemon Papanastasiou; Jean-Yves Reginster; Rene Rizzoli; Luis Russo; Guoqin Su; Dirk Vanderschueren; richard Witvrouw; Jose Zanchetta; Oscar Antunez; Eric Orwoll
Fracture risk and zoledronic acid therapy in men with osteoporosis.
The New England journal of medicine 2012;367(18):1714-23.
2012: René Rizzoli; J J Body; M L Brandi; A De Censi; P Piscitelli; Jean-Yves Reginster
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(11):2567-76.
2012: Olivier Bruyère; Arkadi Chines; Johann Detilleux; Jean-Yves Reginster
Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene.
Calcified tissue international 2012;91(4):244-9.
2012: Véronique Rabenda; Olivier Bruyère; Jean-Yves Reginster
Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants.
Bone 2012;51(4):674-9.
2012: René Rizzoli; G Werhya; S Reiter; J D Adachi; C Cooper; W Dere; J P Devogelaer; Adolfo Diez-Perez; John A Kanis; Andrea Laslop; Bruce H Mitlak; S Papapoulos; S Ralston; Jean-Yves Reginster
Management of glucocorticoid-induced osteoporosis.
Calcified tissue international 2012;91(4):225-43.
2012: Jean-Yves Reginster
In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo.
Evidence-based medicine 2012;17(5):152-3.
2012: Jean-Yves Reginster; Nathalie Sarlet; Marie-Paule Lecart; Audrey Neuprez; Olivier Bruyere
Role of glucosamine in the treatment for osteoarthritis.
Rheumatology international 2012;32(10):2959-67.
2012: Eric Orwoll; Jean-Yves Reginster; Suresh Siddhanti; Christence S Teglbjærg; Rachel B Wagman; Yu-Ching Yang; Osten Ljunggren; Bo Abrahamsen; Michael A Bolognese; Henry G Bone; Roland Chapurlat; Edward Czerwinski; Andreas Grauer; Ugis Gruntmanis; Jesse W Hall; David L Kendler; Alan Kivitz; Bente L Langdahl; E Michael Lewiecki; Michael R McClung; Paul D Miller; Steven Boonen
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.
The Journal of clinical endocrinology and metabolism 2012;97(9):3161-9.
2012: René Rizzoli; B Abrahamsen; J D Adachi; M L Brandi; Olivier Bruyère; J Compston; C Cooper; P Ducy; S Ferrari; N C Harvey; John A Kanis; G Karsenty; Andrea Laslop; Véronique Rabenda; Jean-Yves Reginster; P Vestergaard
Antidepressant medications and osteoporosis.
Bone 2012;51(3):606-13.
2012: Mickaël Hiligsmann; Bernie McGowan; Michael Barry; Kathleen Bennett; Jean-Yves Reginster
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(5):604-12.
2012: Paul D Miller; Robert R Recker; Jean-Yves Reginster; B J Riis; Jacob A Stakkestad; E Czerwinski; A Kenwright; R Lorenc; Daiva Masanauskaite; P Lakatos
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(6):1747-56.
2012: M Hiligsmann; Jean-Yves Reginster
[A changing medical and economic world: complex diseases and interest in economic evaluation of health technologies].
Revue médicale de Liège 2012;67(5-6):258-62.
2012: Jörg Goldhahn; John A Kanis; Bruce H Mitlak; S Papapoulos; Jean-Yves Reginster; R Rizzoli; Yannis Tsouderos; W Dere; J-M Féron; S Boonen
Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.
Calcified tissue international 2012;90(5):343-53.
2012: Mickaël Hiligsmann; Yves Parmentier; Dominique Roberfroid; Olivier Bruyère; Joëlle Carton; Johann Detilleux; Cécile Dubois; Pierre Gillet; Jean-Yves Reginster
Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007).
Arthritis care & research 2012;64(5):744-50.
2012: Mickaël Hiligsmann; Véronique Rabenda; Annelies Boonen; Jean-Yves Reginster
The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
Expert review of pharmacoeconomics & outcomes research 2012;12(2):159-66.
2012: Olivier Bruyère; V Coxam; J Guicheux; G B Guillou; A-E Lugrin; Emmanuel Maheu; Christophe Merceron; T Pauquai; F Rannou; P Richette; L Rovati; Yannis Tsouderos; N Urban; P Ythier-Moury; B Avouac; P Bruel; Jean-Yves Reginster
Health claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science.
Current medical research and opinion 2012;28(4):611-6.
2012: Cyrus Cooper; B Cortet; M Diaz-Curiel; J A Kanis; R S Lorenc; Jean-Yves Reginster; R Rizzoli
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Current medical research and opinion 2012;28(3):475-91.
2012: Jean-Yves Reginster; J Wark; Janusz E Badurski; A Balogh; C L Benhamou; M-L Brandi; Olivier Bruyère; Jean-Pierre Devogelaer; M Diaz-Curiel; Dieter Felsenberg; Stefan Goemaere; Jean-Marc Kaufman; Christian Roux
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(3):1115-22.
2012: Socrates Papapoulos; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Michelle N Bradley; Maria Luisa Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Nadia Daizadeh; Andreas Grauer; Marc-Antoine Krieg; Cesar Libanati; Zulema Man; Dan Mellström; Henry G Bone
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2012;27(3):694-701.
2012: Jean-Jacques Body; Steven Boonen; Jean-Pierre Devogelaer; E Gielen; Stefan Goemaere; Jean-Marc Kaufman; Pierre Bergmann; Serge Rozenberg; Jean-Yves Reginster
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23 Suppl 1():S1-23.
2012: Cyrus Cooper; Harry Genant; Evgeny Nasonov; Federico Navarro; Jean-Yves Reginster; Janusz E Badurski; Nicholas Bellamy; William Bensen; Roland Chapurlat; Xavier Chevalier; Claus Christiansen; Philip N Sambrook
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
Current medical research and opinion 2012;28(2):231-9.
2012: Olivier Bruyère; Jean-Michel Crielaard; Clara Brereton; Maryline Demoulin; Daniel Flynn; Jonathan C Hill; Fabienne Humblet; Didier Maquet; Jean-Yves Reginster; Julien Van Beveren; Christophe Demoulin
Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French.
Archives of public health = Archives belges de santé publique 2012;70(1):12.
2011: Marie-Paule Lecart; Jean-Yves Reginster
Current options for the management of postmenopausal osteoporosis.
Expert opinion on pharmacotherapy 2011;12(16):2533-52.
2011: Jean-Jacques Body; Steven Boonen; Yves Boutsen; O Bruyere; Jean-Pierre Devogelaer; Stefan Goemaere; Nadine Hollevoet; Jean-Marc Kaufman; K Milisen; Pierre Bergmann; Serge Rozenberg; Jean-Yves Reginster
Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(11):2769-88.
2011: Catherine van der Rest; Etienne Cavalier; Roland Hustinx; Jean-François Kaux; Jean-Marie Krzesinski; Jean-Yves Reginster; Pierre Delanaye
Tumor-induced osteomalacia: The tumor may stay hidden!
Clinical biochemistry 2011;44(14-15):1264-6.
2011: Pierre Miossec; B Mitlak; S Mpofu; Sif Ormarsdóttir; C Pitzalis; R Rao; Jean-Yves Reginster; S Reiter; Yannis Tsouderos; C L Verweij; Eric Abadie; A Barton; Ferdinand C Breedveld; W Dere; Dominique Ethgen; Bruno Flamion; N Goel; L Klareskog; Andrea Laslop; Fritz Lekkerkerker
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Annals of the rheumatic diseases 2011;70(10):1713-8.
2011: Mickaël Hiligsmann; Jean-Yves Reginster
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
PharmacoEconomics 2011;29(10):895-911.
2011: John A Kanis; Véronique Rabenda; Jean-Yves Reginster; C Cooper; M Hiligsmann; René Rizzoli
Partial adherence: a new perspective on health economic assessment in osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(10):2565-73.
2011: Josef S Smolen; Eric C Abadie; Bernard P Avouac; Thomas Bardin; Maarten Boers; Ferdinand C Breedveld; Patrick Durez; Paul Emery; Dominique J Ethgen; Bruno Flamion; Niti Goel; Andrea Laslop; Pierre Miossec; Jean-Yves Reginster; Susanne Reiter
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
Rheumatology (Oxford, England) 2011;50(10):1732-6.
2011: Stuart H Ralston; Neil Binkley; Steven Boonen; Douglas P Kiel; Jean-Yves Reginster; Christian Roux; Liang Chen; Elizabeth Rosenberg; Arthur Santora
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Calcified tissue international 2011;88(6):485-94.
2011: Véronique Rabenda; Olivier Bruyère; Jean-Yves Reginster
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(3):893-901.
2011: Philippe Musette; Maria Louisa Brandi; Patrice Cacoub; Jean-Marc Kaufman; René Rizzoli; Jean-Yves Reginster
Cutaneous side effects of antiosteoporosis treatments.
Therapeutic advances in musculoskeletal disease 2011;3(1):31-41.
2011: Josef S Smolen; Maarten Boers; Eric C Abadie; Ferdinand C Breedveld; Paul Emery; Thomas Bardin; Niti Goel; Dominique J Ethgen; Bernard P Avouac; Willard H Dere; Patrick Durez; Marco Matucci-Cerinic; Bruno Flamion; Andrea Laslop; Frits J Lekkerkerker; Pierre Miossec; Bruce H Mitlak; Sif Ormarsdóttir; Laurence Paolozzi; Ravi Rao; Susan Reiter; Yannis Tsouderos; Jean-Yves Reginster
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
Current medical research and opinion 2011;27(2):315-25.
2011: René Rizzoli; K Akesson; Mary L Bouxsein; John A Kanis; N Napoli; S Papapoulos; Jean-Yves Reginster; C Cooper
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(2):373-90.
2011: Steven R Cummings; Michael R McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak; John Stock; Messan Amewou-Atisso; Trevor Powles; Paul Miller; José Zanchetta; Claus Christiansen
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2011;26(2):397-404.
2011: Helena Johansson; John A Kanis; Eugene McCloskey; A Odén; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Audrey Neuprez; M Hiligsmann; Olivier Bruyere; Jean-Yves Reginster
A FRAX® model for the assessment of fracture probability in Belgium.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(2):453-61.
2011: Jean-Yves Reginster
Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Drugs 2011;71(1):65-78.
2010: Véronique Rabenda; Jean-Yves Reginster
Overcoming problems with adherence to osteoporosis medication.
Expert review of pharmacoeconomics & outcomes research 2010;10(6):677-89.
2010: Jean-Yves Reginster; Audrey Neuprez
Strontium ranelate: a look back at its use for osteoporosis.
Expert opinion on pharmacotherapy 2010;11(17):2915-27.
2010: Véronique Rabenda; Jean-Yves Reginster
Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(12):1993-2002.
2010: Jean-Jacques Body; Pierre Bergmann; Steven Boonen; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(10):1657-80.
2010: Mickaël Hiligsmann; Marie Vanoverberghe; Audrey Neuprez; Olivier Bruyère; Jean-Yves Reginster
Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
Expert review of pharmacoeconomics & outcomes research 2010;10(4):359-66.
2010: Jean-Yves Reginster
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96.
Expert opinion on pharmacotherapy 2010;11(10):1773-5.
2010: Mickaël Hiligsmann; Jean-Yves Reginster
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Bone 2010;47(1):34-40.
2010: Mickaël Hiligsmann; Véronique Rabenda; Olivier Bruyère; Jean-Yves Reginster
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
Health policy (Amsterdam, Netherlands) 2010;96(2):170-7.
2010: Jean-Yves Reginster; Mickaël Hiligsmann; Olivier Bruyere
Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.
Therapeutic advances in musculoskeletal disease 2010;2(3):133-43.
2010: Mickaël Hiligsmann; Henry-Jean Gathon; Olivier Bruyère; Olivier Ethgen; Véronique Rabenda; Jean-Yves Reginster
Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2010;13(4):394-401.
2010: Olivier Bruyère; Julien Collette; René Rizzoli; C Decock; S Ortolani; C Cormier; J Detilleux; Jean-Yves Reginster
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(6):1031-6.
2010: S Scholtissen; Olivier Bruyère; Audrey Neuprez; J L Severens; G Herrero-Beaumont; L Rovati; M Hiligsmann; Jean-Yves Reginster
Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol.
International journal of clinical practice 2010;64(6):756-62.
2010: Olivier Bruyere; John A Kanis; M-E Ibar-Abadie; N Alsayed; M L Brandi; Nansa Burlet; D L Cahall; A Chines; Jean-Pierre Devogelaer; W Dere; N Goel; N Hughes; Jean-Marc Kaufman; S Korte; Bruce H Mitlak; D Niese; René Rizzoli; L C Rovati; Jean-Yves Reginster
The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(5):713-22.
2010: Ego Seeman; Steven Boonen; Frederik Borgström; Bruno Vellas; Jean-Pierre Aquino; Jutta Semler; Claude-Laurent Benhamou; Jean-Marc Kaufman; Jean-Yves Reginster
Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Bone 2010;46(4):1038-42.
2010: Mickaël Hiligsmann; Véronique Rabenda; Henry-Jean Gathon; Olivier Ethgen; Jean-Yves Reginster
Potential clinical and economic impact of nonadherence with osteoporosis medications.
Calcified tissue international 2010;86(3):202-10.
2010: Mickaël Hiligsmann; Olivier Bruyère; Jean-Yves Reginster
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Bone 2010;46(2):440-6.
2010: Julien Collette; Olivier Bruyère; Jean-Marc Kaufman; R Lorenc; Dieter Felsenberg; T D Spector; M Diaz-Curiel; S Boonen; Jean-Yves Reginster
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(2):233-41.
2010: Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; J Kaufman; Jean-Yves Reginster; Serge Rozenberg
Loading and skeletal development and maintenance.
Journal of osteoporosis 2010;2011():786752.
2010: Jean-Yves Reginster; Roy D Altman; Marc C Hochberg
Glucosamine and osteoarthritis. Prescribed regimen is effective.
BMJ (Clinical research ed.) 2010;341():c6335.
2010: M Hiligsmann; Olivier Bruyère; Jean-Yves Reginster
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(1):157-65.
2009: Audrey Neuprez; H Johansson; J A Kanis; E V McCloskey; A Odén; Olivier Bruyère; M Hiligsmann; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Jean-Yves Reginster
[A FRAX model for the assessment of fracture probability in Belgium].
Revue médicale de Liège 2009;64(12):612-9.
2009: Jean-Yves Reginster; Olivier Bruyère; A Sawicki; A Roces-Varela; Patrice Fardellone; A Roberts; Jean-Pierre Devogelaer
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Bone 2009;45(6):1059-64.
2009: Audrey Neuprez; M Hiligsmann; Olivier Bruyère; Jean-Yves Reginster
[Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice].
Revue médicale de Liège 2009;64(10):525-9.
2009: René Rizzoli; O Bruyere; J B Cannata-Andia; J -P Devogelaer; G Lyritis; J D Ringe; Bruno Vellas; Jean-Yves Reginster
Management of osteoporosis in the elderly.
Current medical research and opinion 2009;25(10):2373-87.
2009: Véronique Rabenda; Michaël Hiligsmann; Jean-Yves Reginster
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
Expert opinion on pharmacotherapy 2009;10(14):2303-15.
2009: Florent Richy; Carmelo Scarpignato; Angel Lanas; Jean-Yves Reginster
Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(4):254-63.
2009: Pierre J Meunier; C Roux; S Ortolani; M Diaz-Curiel; Juliet E Compston; P Marquis; C Cormier; G Isaia; J Badurski; J D Wark; J Collette; Jean-Yves Reginster
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2009;20(10):1663-73.
2009: Jean-Yves Reginster; Rita Deroisy; Audrey Neuprez; Mickaël Hiligsmann; Brigitte Zegels; Olivier Bruyere
Strontium ranelate: new data on fracture prevention and mechanisms of action.
Current osteoporosis reports 2009;7(3):96-102.
2009: Mickaël Hiligsmann; Olivier Ethgen; Olivier Bruyère; Florent Richy; Henry-Jean Gathon; Jean-Yves Reginster
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12(5):687-96.
2009: S Scholtissen; F Guillemin; Olivier Bruyère; Julien Collette; B Dousset; C Kemmer; S Culot; D Crémer; H Dejardin; G Hubermont; D Lefebvre; V Pascal-Vigneron; G Weryha; Jean-Yves Reginster
Assessment of determinants for osteoporosis in elderly men.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2009;20(7):1157-66.
2009: Steven T Harris; Jean-Yves Reginster; C Harley; William A Blumentals; S A Poston; Charles Barr; S L Silverman
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Bone 2009;44(5):758-65.
2009: David M Reid; Jean-Pierre Devogelaer; Kenneth G Saag; Christian Roux; Chak Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet 2009;373(9671):1253-63.
2009: André Kahan; Daniel Uebelhart; Florent de Vathaire; Pierre D Delmas; Jean-Yves Reginster
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2009;60(2):524-33.
2009: Olivier Bruyère; S Scholtissen; Audrey Neuprez; M Hiligsmann; A Toukouki; Jean-Yves Reginster
Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.
Journal of medical economics 2009;12(4):356-60.
2009: Olivier Bruyere; Alfredo Roces Varela; Silvio Adami; Johann Detilleux; Véronique Rabenda; Mickael Hiligsmann; Jean-Yves Reginster
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.
European journal of epidemiology 2009;24(11):707-12.
2009: Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Jean-Yves Reginster; Valérie Gangji
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.
International journal of clinical practice 2009;63(1):19-26.
2009: Olivier Bruyere; Caroline Decock; Melanie Delhez; Julien Collette; Jean-Yves Reginster
Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study.
Women's health (London, England) 2009;5(1):49-54.
2008: Linda Hanssens; Ruud van Winkel; Martien Wampers; Dominique Van Eyck; Andre Scheen; Jean-Yves Reginster; Julien Collette; Joseph Peuskens; Marc De Hert
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Schizophrenia research 2008;106(2-3):308-14.
2008: Mickaël Hiligsmann; Olivier Bruyère; Olivier Ethgen; Henry-Jean Gathon; Jean-Yves Reginster
Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women.
Bone 2008;43(6):991-4.
2008: John A Kanis; Jean-Yves Reginster
European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice?
Polskie Archiwum Medycyny Wewnętrznej 2008;118(10):538-40.
2008: Audrey Neuprez; Jean-Yves Reginster
Bone-forming agents in the management of osteoporosis.
Best practice & research. Clinical endocrinology & metabolism 2008;22(5):869-83.
2008: M Hiligsmann; Olivier Bruyère; Grégory A Pire; Jean-Yves Reginster
[Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé].
Revue médicale de Liège 2008;63(10):588-94.
2008: Véronique Rabenda; Johan Vanoverloop; Valérie Fabri; Raf Mertens; François Sumkay; Carine Vannecke; André Deswaef; Gert A Verpooten; Jean-Yves Reginster
Low incidence of anti-osteoporosis treatment after hip fracture.
The Journal of bone and joint surgery. American volume 2008;90(10):2142-8.
2008: Olivier Bruyere; M-L Brandi; Nansa Burlet; N Harvey; G Lyritis; H Minne; S Boonen; Jean-Yves Reginster; René Rizzoli; K Akesson
Post-fracture management of patients with hip fracture: a perspective.
Current medical research and opinion 2008;24(10):2841-51.
2008: Caroline De Cock; Olivier Bruyere; Julien Collette; Jean-Yves Reginster
Vitamin D inadequacy in French osteoporotic and osteopenic women.
Joint, bone, spine : revue du rhumatisme 2008;75(5):567-72.
2008: Thomas M MacDonald; Jean-Yves Reginster; Thomas W Littlejohn; Dominik Richard; Karine Lheritier; Gerhard Krammer; Rosemary Rebuli
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Journal of hypertension 2008;26(8):1695-702.
2008: Jörg Goldhahn; Wim H Scheele; Bruce H Mitlak; Eric Abadie; Per Aspenberg; Peter Augat; Maria-Luisa Brandi; Nansa Burlet; Arkadi Chines; Pierre D Delmas; Isabelle Dupin-Roger; Dominique Ethgen; Beate Hanson; Florian Hartl; John A Kanis; Reshma Kewalramani; Andrea Laslop; David Marsh; Sif Ormarsdottir; René Rizzoli; Art Santora; Gerhard Schmidmaier; Michael Wagener; Jean-Yves Reginster
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
Bone 2008;43(2):343-7.
2008: Jean-Pierre Devogelaer; P Bergmann; Jean-Jacques Body; Yves Boutsen; Stefan Goemaere; Jean-Marc Kaufman; Jean-Yves Reginster; Serge Rozenberg; S Boonen
Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008;19(8):1109-17.
2008: Jacob A Stakkestad; Peter Lakatos; Roman Lorenc; Farhad Sedarati; Colin Neate; Jean-Yves Reginster
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
Clinical rheumatology 2008;27(8):955-60.
2008: M Hiligsmann; Olivier Bruyère; Jean-Yves Reginster
[Long-term risk of osteoporotic fracture in Belgium].
Revue médicale de Liège 2008;63(7-8):480-7.
2008: Jean-Yves Reginster; Audrey Neuprez; Olivier Bruyère
Ibandronate in profile: drug characteristics and clinical efficacy.
Expert opinion on drug metabolism & toxicology 2008;4(7):941-51.
2008: Jean-Yves Reginster; Dieter Felsenberg; Steven Boonen; Adolfo Diez-Perez; Rene Rizzoli; Maria-Luisa Brandi; Tim D Spector; Kim Brixen; Stefan Goemaere; Catherine Cormier; Adam Balogh; Pierre D Delmas; Pierre J Meunier
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Arthritis and rheumatism 2008;58(6):1687-95.
2008: Véronique Rabenda; R Mertens; V Fabri; J Vanoverloop; F Sumkay; C Vannecke; A Deswaef; G A Verpooten; Jean-Yves Reginster
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008;19(6):811-8.
2008: Jean-Yves Reginster; Julien Collette; Audrey Neuprez; Brigitte Zegels; Rita Deroisy; Olivier Bruyere
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
Bone 2008;42(5):832-6.
2008: René Rizzoli; Nansa Burlet; David Cahall; Pierre D Delmas; Erik Fink Eriksen; Dieter Felsenberg; John Grbic; Mats Jontell; Regina Landesberg; Andrea Laslop; Martina Wollenhaupt; Socrates Papapoulos; Orhan Sezer; Michael Sprafka; Jean-Yves Reginster
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Bone 2008;42(5):841-7.
2008: Mickaël Hiligsmann; Olivier Ethgen; Florent Richy; Jean-Yves Reginster
Utility values associated with osteoporotic fracture: a systematic review of the literature.
Calcified tissue international 2008;82(4):288-92.
2008: John A Kanis; N Burlet; C Cooper; P D Delmas; Jean-Yves Reginster; Frederik Borgstrom; Rene Rizzoli
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008;19(4):399-428.
2008: John A Eisman; Roberto Civitelli; Silvano Adami; Edward Czerwinski; Chris Recknor; Richard Prince; Jean-Yves Reginster; Mone Zaidi; Dieter Felsenberg; Claire Hughes; Nicole Mairon; Daiva Masanauskaite; David M Reid; Pierre D Delmas; Robert R Recker
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
The Journal of rheumatology 2008;35(3):488-97.
2008: Ego Seeman; Jean-Pierre Devogelaer; Roman Lorenc; Timothy Spector; Kim Brixen; Adam Balogh; Gerold Stucki; Jean-Yves Reginster
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2008;23(3):433-8.
2008: Olivier Bruyere; D Delferriere; Christian Roux; J D Wark; T Spector; Jean-Pierre Devogelaer; Kim Brixen; Silvano Adami; Jacques Fechtenbaum; Sami Kolta; Jean-Yves Reginster
Effects of strontium ranelate on spinal osteoarthritis progression.
Annals of the rheumatic diseases 2008;67(3):335-9.
2008: Jörg Goldhahn; Bruce Mitlak; Per Aspenberg; John A Kanis; René Rizzoli; Jean-Yves Reginster
Critical issues in translational and clinical research for the study of new technologies to enhance bone repair.
The Journal of bone and joint surgery. American volume 2008;90 Suppl 1():43-7.
2008: René Rizzoli; S Boonen; M L Brandi; Nansa Burlet; P Delmas; Jean-Yves Reginster
The role of calcium and vitamin D in the management of osteoporosis.
Bone 2008;42(2):246-9.
2008: Olivier Bruyere; Karel Pavelka; Lucio C Rovati; Jindriska Gatterová; Giampaolo Giacovelli; M Olejarová; Rita Deroisy; Jean-Yves Reginster
Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2008;16(2):254-60.
2008: Olivier Bruyère; Nansa Burlet; Pierre D Delmas; René Rizzoli; Cyrus Cooper; Jean-Yves Reginster
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
BMC musculoskeletal disorders 2008;9():165.
2008: Roy Fleischmann; Hyman Tannenbaum; Neha P Patel; Marianne Notter; Peter Sallstig; Jean-Yves Reginster
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
BMC musculoskeletal disorders 2008;9():32.
2008: Paul D Miller; Sol Epstein; Farhad Sedarati; Jean-Yves Reginster
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Current medical research and opinion 2008;24(1):207-13.
2007: Olivier Bruyère; Christian Roux; Janusz E Badurski; G Isaia; M C de Vernejoul; J Cannata; Sergio Ortolani; D Slosman; Johann Detilleux; Jean-Yves Reginster
Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.
Current medical research and opinion 2007;23(12):3041-5.
2007: Jean-Yves Reginster; Nansa Burlet; Pierre Close; Olivier Bruyere
Injectable bisphosphonates for the treatment of osteoporosis.
Women's health (London, England) 2007;3(6):719-23.
2007: Jean-Yves Reginster
[Strontium ranlelate (Protelos)].
Revue médicale de Liège 2007;62(11):685-7.
2007: Jean-Jacques Body; P Bergmann; Steven Boonen; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Yves Reginster; Serge Rozenberg; Jean-Marc Kaufman
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2007;18(11):1439-50.
2007: Jean-Yves Reginster; Florence Heraud; Brigitte Zegels; Olivier Bruyere
Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis.
Mini reviews in medicinal chemistry 2007;7(10):1051-61.
2007: Fritz Lekkerkerker; John A Kanis; N Alsayed; G Bouvenot; Nansa Burlet; D Cahall; A Chines; P Delmas; Renèe-Liliane Dreiser; Dominique Ethgen; N Hughes; Jean-Marc Kaufman; S Korte; Gottfried Kreutz; Andrea Laslop; Bruce H Mitlak; Véronique Rabenda; R Rizzoli; A Santora; R Schimmer; Yannis Tsouderos; P Viethel; Jean-Yves Reginster
Adherence to treatment of osteoporosis: a need for study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2007;18(10):1311-7.
2007: Annalisa Tancredi; Jean-Jacques Legros; Georges Pire; Philippe Maassen; Françoise Luyckx; Jean-Yves Reginster
Analysis of the discriminant ability of shorter versions of the French ADAM questionnaire.
The aging male : the official journal of the International Society for the Study of the Aging Male 2007;10(3):159-64.
2007: Jean-Yves Reginster
Calcium and vitamin D for osteoporotic fracture risk.
Lancet 2007;370(9588):632-4.
2007: Olivier Malaise; Olivier Bruyere; Jean-Yves Reginster
Strontium ranelate normalizes bone mineral density in osteopenic patients.
Aging clinical and experimental research 2007;19(4):330-3.
2007: Olivier Bruyère; Olivier Malaise; Audrey Neuprez; Julien Collette; Jean-Yves Reginster
Prevalence of vitamin D inadequacy in European postmenopausal women.
Current medical research and opinion 2007;23(8):1939-44.
2007: Florent Richy; Véronique Rabenda; Audrey Mawet; Jean-Yves Reginster
Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative.
International journal of clinical practice 2007;61(8):1396-406.
2007: Olivier Bruyere; Christian Roux; Johann Detilleux; Daniel O Slosman; Tim D Spector; Patrice Fardellone; Kim Brixen; Jean-Pierre Devogelaer; Manuel Diaz-Curiel; Carlina Albanese; Jean-Marc Kaufman; Stig Pors-Nielsen; Jean-Yves Reginster
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
The Journal of clinical endocrinology and metabolism 2007;92(8):3076-81.
2007: Jean-Yves Reginster
[Osteoporosis treatment: choices and options].
Polskie Archiwum Medycyny Wewnętrznej 2007;117(7):283-4.
2007: Jean-Yves Reginster
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.
Arthritis and rheumatism 2007;56(7):2105-10.
2007: Jean-Yves Reginster
[Advances in the treatment of postmenopausal osteoporosis].
Revue médicale de Liège 2007;62(5-6):352-9.
2007: Jean-Yves Reginster; Olivier Bruyere; Audrey Neuprez
Current role of glucosamine in the treatment of osteoarthritis.
Rheumatology (Oxford, England) 2007;46(5):731-5.
2007: Véronique Rabenda; Christelle Manette; Régine Lemmens; Anne-Marie Mariani; Nicole Struvay; Jean-Yves Reginster
Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects.
Aging clinical and experimental research 2007;19(1):55-60.
2007: Jean-Yves Reginster; Olivier Malaise; Audrey Neuprez; Olivier Bruyere
Strontium ranelate in the prevention of osteoporotic fractures.
International journal of clinical practice 2007;61(2):324-8.
2007: Olivier Bruyere; Jean-Yves Reginster
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.
Drugs & aging 2007;24(7):573-80.
2007: Jean-Yves Reginster; Olivier Malaise; Audrey Neuprez; Victor-Emmanuel Jouret; Pierre Close
Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
Drugs & aging 2007;24(5):351-9.
2007: Audrey Neuprez; Olivier Bruyère; Julien Collette; Jean-Yves Reginster
Vitamin D inadequacy in Belgian postmenopausal osteoporotic women.
BMC public health 2007;7():64.
2007: Stefan Goemaere; Dirk Vanderschueren; Jean-Marc Kaufman; Jean-Yves Reginster; Yves Boutsen; Stefaan Poriau; Joris Callens; Frank Raeman; Genevieve Depresseux; Herman Borghs; Jean-Pierre Devogelaer; Steven Boonen
Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2007;10(1):25-33.
2007: Olivier Bruyere; Harry K Genant; Manish Kothari; Souhil Zaim; D White; Charles Peterfy; Nansa Burlet; Florent Richy; Dominique Ethgen; T Montague; C Dabrowski; Jean-Yves Reginster
Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2007;15(1):98-103.
2006: Jean-Yves Reginster; R Gieschke
Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
Current drug metabolism 2006;7(7):827-36.
2006: Pierre Close; Audrey Neuprez; Jean-Yves Reginster
Developments in the pharmacotherapeutic management of osteoporosis.
Expert opinion on pharmacotherapy 2006;7(12):1603-15.
2006: Pierre D Delmas; A A Licata; Jean-Yves Reginster; G G Crans; Peiqi Chen; Derek A Misurski; Rachel B Wagman; B H Mitlak
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Bone 2006;39(2):237-43.
2006: Olivier Bruyere; Julien Collette; Manish Kothari; Souhil Zaim; D White; Harry K Genant; Charles Peterfy; Nansa Burlet; Dominique Ethgen; T Montague; C Dabrowski; Jean-Yves Reginster
Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study.
Annals of the rheumatic diseases 2006;65(8):1050-4.
2006: Ego Seeman; Bruno Vellas; Claude Benhamou; Jean Pierre Aquino; Jutta Semler; Jean Marc Kaufman; Krzysztof Hoszowski; Alfredo Roces Varela; Carmelo Fiore; Kim Brixen; Jean-Yves Reginster; Steven Boonen
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006;21(7):1113-20.
2006: Olivier Bruyere; Jean-Yves Reginster; Giampaolo Giacovelli; Beatrice Barbetta; Lucio C Rovati; Karel Pavelka
Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca.
Arthritis and rheumatism 2006;54(7):2339-41; author reply 2341-3.
2006: Véronique Rabenda; Nansa Burlet; J Belaiche; F Raeman; Florent Richy; Jean-Yves Reginster
Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2006;14(7):625-30.
2006: Véronique Rabenda; Christelle Manette; Régine Lemmens; Anne-Marie Mariani; Nicole Struvay; Jean-Yves Reginster
Direct and indirect costs attributable to osteoarthritis in active subjects.
The Journal of rheumatology 2006;33(6):1152-8.
2006: Pierre D Delmas; Silvano Adami; Cezary Strugala; Jacob A Stakkestad; Jean-Yves Reginster; Dieter Felsenberg; Claus Christiansen; Roberto Civitelli; Marc K Drezner; Robert R Recker; Michael A Bolognese; Claire Hughes; Daiva Masanauskaite; Penelope Ward; Philip Sambrook; David M Reid
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Arthritis and rheumatism 2006;54(6):1838-46.
2006: Florent Richy; Marie-Paule Lecart; Audrey Mawet; B Paquot; Jean-Yves Reginster
[Value of bone densitometry for the diagnosis and monitoring of osteoporotic patients: integration with biological and clinical risk factors].
Revue médicale de Liège 2006;61(5-6):291-300.
2006: Steven Boonen; Heike A Bischoff-Ferrari; C Cooper; P Lips; O Ljunggren; P J Meunier; Jean-Yves Reginster
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence.
Calcified tissue international 2006;78(5):257-70.
2006: Jean-Yves Reginster; Silvano Adami; P Lakatos; M Greenwald; Jan J Stepan; Stuart L Silverman; C Christiansen; L Rowell; N Mairon; Bernard Bonvoisin; Marc K Drezner; R Emkey; Dieter Felsenberg; Cyrus Cooper; Pierre D Delmas; Paul D Miller
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Annals of the rheumatic diseases 2006;65(5):654-61.
2006: Audrey Neuprez; Philippe Gillet; Catherine Collette; Jean-Yves Reginster
[Bone densitometry for the diagnosis of osteoporosis: the Belgian reimbursement paradox].
Revue médicale de Liège 2006;61(4):249-55.
2006: Christian Roux; Jean-Yves Reginster; Jacques Fechtenbaum; Sami Kolta; Andrzej Sawicki; Zsolt Tulassay; Giovanni Luisetto; José-Maria Padrino; David Doyle; Richard Prince; Patrice Fardellone; Ole Helmer Sorensen; Pierre Jean Meunier
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006;21(4):536-42.
2006: Jean-Yves Reginster; Véronique Rabenda; Audrey Neuprez
Adherence, patient preference and dosing frequency: understanding the relationship.
Bone 2006;38(4 Suppl 1):S2-6.
2006: Jean-Yves Reginster; Florent Richy; Olivier Bruyere
[Glucosamine as a pain-modifying drug in osteorthritis. What's new in 2006].
Revue médicale de Liège 2006;61(3):169-72.
2006: Nansa Burlet; Jean-Yves Reginster
Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis.
Clinical orthopaedics and related research 2006;443():55-60.
2006: Jean-Yves Reginster; Jean-Pierre Devogelaer
Raloxifene reduces fractures in postmenopausal women with osteoporosis.
Clinical orthopaedics and related research 2006;443():48-54.
2006: Jean-Yves Reginster; Nansa Burlet
Osteoporosis: a still increasing prevalence.
Bone 2006;38(2 Suppl 1):S4-9.
2006: Jean-Yves Reginster
Adherence and persistence: impact on outcomes and health care resources.
Bone 2006;38(2 Suppl 2):S18-21.
2006: Michael C Nevitt; Peiqi Chen; Robin K Dore; Jean-Yves Reginster; Douglas P Kiel; Jose R Zanchetta; Emmett Glass; John Krege
Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(2):273-80.
2006: Jean-Yves Reginster; Dieter Felsenberg; Cyrus Cooper; Jacob A Stakkestad; Paul D Miller; David L Kendler; Silvano Adami; Michael R McClung; Michael A Bolognese; Roberto Civitelli; Etienne Dumont; Bernard Bonvoisin; Robert R Recker; Pierre D Delmas
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(2):159-66.
2006: Jean-Yves Reginster; Véronique Rabenda
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates.
Clinical interventions in aging 2006;1(4):415-23.
2006: Michael C Nevitt; Peiqi Chen; D P Kiel; Jean-Yves Reginster; R K Dore; J R Zanchetta; Emmett Glass; John Krege
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(11):1630-7.
2006: Véronique Rabenda; Christelle Manette; Régine Lemmens; Anne-Marie Mariani; Nicole Struvay; Jean-Yves Reginster
The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(9):1346-52.
2006: Christelle Manette; Julien Collette; Nathalie Sarlet; Annalisa Tancredi; Brigitte Zegels; Jean-Yves Reginster
Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate.
Current medicinal chemistry 2006;13(13):1585-90.
2006: Linda Hanssens; Marc De Hert; Martien Wampers; Jean-Yves Reginster; Joseph Peuskens
Pharmacological treatment of ambulatory schizophrenic patients in Belgium.
Clinical practice and epidemiology in mental health : CP & EMH 2006;2():11.
2006: Lucio C Rovati; Karel Pavelka; Giampaolo Giacovelli; Jean-Yves Reginster
Assessment of joint space narrowing with conventional standing antero-posterior radiographs: relief in mild-to-moderate pain is not a confounder in recent osteoarthritis structure-modifying drug trials.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2006;14 Suppl A():A14-8.
2006: Jean-Yves Reginster; Nathalie Sarlet
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
Treatments in endocrinology 2006;5(1):15-23.
2006: Ana Munoz; John Krege; Peiqi Chen; Emmett Glass; Jean-Yves Reginster
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
Current medical research and opinion 2006;22(1):61-6.
2006: Jean-Pierre Devogelaer; Stefan Goemaere; Steven Boonen; Jean-Jacques Body; Jean-Marc Kaufman; Jean-Yves Reginster; Serge Rozenberg; Yves Boutsen
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(1):8-19.
2006: Jean-Yves Reginster; Eric Abadie; Pierre Delmas; René Rizzoli; Willard Dere; Philippevan der Auwera; Bernard Avouac; Maria-Luisa Brandi; Anastasia G Daifotis; Adolfo Diez-Perez; Gonzalo Calvo; Olof Johnell; Jean-Marc Kaufman; Gottfried Kreutz; Andrea Laslop; Fritz Lekkerkerker; Bruce H Mitlak; Per Nilsson; John J Orloff; Mary Smillie; Andrew Taylor; Yannis Tsouderos; Dominique Ethgen; Bruno Flamion
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(1):1-7.
2005: Michelle A Deberg; Alain Labasse; Julien Collette; Laurence Seidel; Jean-Yves Reginster; Yves Henrotin
One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(12):1059-65.
2005: Olivier Bruyere; Florent Richy; Jean-Yves Reginster
Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study.
Annals of the rheumatic diseases 2005;64(12):1727-30.
2005: Christelle Sanchez; Michelle A Deberg; Nathalie Piccardi; Philippe Msika; Jean-Yves Reginster; Yves Henrotin
Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(11):979-87.
2005: Christelle Sanchez; Michelle A Deberg; Nathalie Piccardi; Philippe Msika; Jean-Yves Reginster; Yves Henrotin
Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(11):988-97.
2005: Jean-Yves Reginster
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Expert opinion on pharmacotherapy 2005;6(13):2301-13.
2005: Jean-Yves Reginster; Marie-Paule Lecart; Florent Richy
Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
The Journal of rheumatology. Supplement 2005;76():21-5.
2005: Jean-Yves Reginster; Katie M Wilson; Etienne Dumont; Bernard Bonvoisin; Joanne Barrett
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
The Journal of clinical endocrinology and metabolism 2005;90(9):5018-24.
2005: Eric C Abadie; Jean-Pierre Devogealer; Johann D Ringe; Dominique Ethgen; Gilles M Bouvenot; Gottfried Kreutz; Andrea Laslop; John J Orloff; Philippe M Vanderauwera; Pierre D Delmas; Willard H Dere; Jaime Branco; Roy D Altman; Bernard P Avouac; Charles J Menkes; Luc VanHaelst; Bruce H Mitlak; Yannis Tsouderos; Jean-Yves Reginster
Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
Seminars in arthritis and rheumatism 2005;35(1):1-4.
2005: Margaret L Gourlay; William C Miller; Florent Richy; Joanne M Garrett; Laura C Hanson; Jean-Yves Reginster
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(8):921-7.
2005: Paul D Miller; Michael R McClung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(8):1315-22.
2005: Annalisa Tancredi; Jean-Yves Reginster; Françoise Luyckx; Jean-Jacques Legros
No major month to month variation in free testosterone levels in aging males. Minor impact on the biological diagnosis of 'andropause'.
Psychoneuroendocrinology 2005;30(7):638-46.
2005: Annie W C Kung; Andrew Y Y Ho; Philip Ross; Jean-Yves Reginster
Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(7):849-55.
2005: Olivier Bruyere; John Edwards; Jean-Yves Reginster
Fracture prevention in postmenopausal women.
Clinical evidence 2005;(13):1419-34.
2005: Jean-Yves Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; Jean-Pierre Devogelaer; M Diaz Curiel; A Sawicki; Stefan Goemaere; Ole Helmer Sorensen; Dieter Felsenberg; P J Meunier
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
The Journal of clinical endocrinology and metabolism 2005;90(5):2816-22.
2005: Véronique Rabenda; Nansa Burlet; Olivier Ethgen; F Raeman; J Belaiche; Jean-Yves Reginster
A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs.
Annals of the rheumatic diseases 2005;64(5):688-93.
2005: Jean-Yves Reginster
Treatment of postmenopausal osteoporosis.
BMJ (Clinical research ed.) 2005;330(7496):859-60.
2005: Florent Richy; Rita Deroisy; Marie-Paule Lecart; Linda Hanssens; Audrey Mawet; Jean-Yves Reginster
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management.
Aging clinical and experimental research 2005;17(2):133-42.
2005: Jean-Yves Reginster
The high prevalence of inadequate serum vitamin D levels and implications for bone health.
Current medical research and opinion 2005;21(4):579-86.
2005: Isabelle Jupsin; Julien Collette; Yves Henrotin; Olivier Bruyere; Nathalie Sarlet; Jean-Yves Reginster
Strontium ranelate (Fujisawa/Servier).
Current opinion in investigational drugs (London, England : 2000) 2005;6(4):435-44.
2005: Jean-Yves Reginster; Nathalie Sarlet; Eric Lejeune; Lorenzo Leonori
Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action.
Current osteoporosis reports 2005;3(1):30-4.
2005: Michelle A Deberg; Alain Labasse; Stephan Christgau; Paul Cloos; Dennis Bang Henriksen; Jean-Pierre Chapelle; Brigitte Zegels; Jean-Yves Reginster; Yves Henrotin
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(3):258-65.
2005: Steven Boonen; Jean-Jacques Body; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(3):239-54.
2005: Florent Richy; E Schacht; Olivier Bruyere; Olivier Ethgen; Margaret L Gourlay; Jean-Yves Reginster
Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Calcified tissue international 2005;76(3):176-86.
2005: Olivier Bruyere; Marc-Antoine Wuidart; Elio Di Palma; Margaret L Gourlay; Olivier Ethgen; Florent Richy; Jean-Yves Reginster
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents.
Archives of physical medicine and rehabilitation 2005;86(2):303-7.
2005: Jean-Yves Reginster; Olivier Bruyere; Genevieve Fraikin; Yves Henrotin
Current concepts in the therapeutic management of osteoarthritis with glucosamine.
Bulletin (Hospital for Joint Diseases (New York, N.Y.)) 2005;63(1-2):31-6.
2005: Jean-Yves Reginster
Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Current pharmaceutical design 2005;11(28):3711-28.
2005: Marianne Mathy-Hartert; S Burton; Ginette Deby-Dupont; Philippe Devel; Jean-Yves Reginster; Yves Henrotin
Influence of oxygen tension on nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(1):74-9.
2005: Roy D Altman; Eric Abadie; Bernard Avouac; Gilles Bouvenot; Jaime Branco; Olivier Bruyere; Gonzalo Calvo; Jean-Pierre Devogelaer; Renèe-Liliane Dreiser; Gabriel Herrero-Beaumont; A Kahan; Gottfried Kreutz; Andrea Laslop; Ernst-Martin Lemmel; C J Menkes; Karel Pavelka; L B A Van De Putte; Luc VanHaelst; Jean-Yves Reginster
Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(1):13-9.
2005: Jean-Yves Reginster; Nathalie Sarlet; MP Lecart
Fractures in osteoporosis: the challenge for the new millennium.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16 Suppl 1():S1-3.
2005: Pierre D Delmas; René Rizzoli; Cyrus Cooper; Jean-Yves Reginster
Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(1):1-5.
2004: Marie-Paule Lecart; Olivier Bruyere; Jean-Yves Reginster
Combination/sequential therapy in osteoporosis.
Current osteoporosis reports 2004;2(4):123-30.
2004: Florent Richy; Olivier Ethgen; Olivier Bruyere; Audrey Mawet; Jean-Yves Reginster
Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(12):1955-60.
2004: Florent Richy; Fréderic Deceulaer; Olivier Ethgen; Olivier Bruyère; Jean-Yves Reginster
Development and validation of the ORACLE score to predict risk of osteoporosis.
Mayo Clinic proceedings. Mayo Clinic 2004;79(11):1402-8.
2004: Robert Lindsay; Wim H Scheele; Robert M Neer; Gerhardt Pohl; Silvano Adami; Carlos Mautalen; Jean-Yves Reginster; Jan J Stepan; Stephen L Myers; Bruce H Mitlak
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Archives of internal medicine 2004;164(18):2024-30.
2004: Wafa Ben Sedrine; Olivier Ethgen; Jean-Pierre Devogelaer; Geneviève Depresseux; Jean-Marc Kaufman; Stefan Goemaere; Jean-Yves Reginster
Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening?
Aging clinical and experimental research 2004;16(5):413-9.
2004: Olivier Ethgen; Daniel Gillain; Pierre Gillet; Christiane Gosset; Alain Jousten; Jean-Yves Reginster
Age- and sex-stratified prevalence of physical disabilities and handicap in the general population.
Aging clinical and experimental research 2004;16(5):389-97.
2004: Christelle Sanchez; Michelle A Deberg; Sandrine Burton; Philippe Devel; Jean-Yves Reginster; Yves Henrotin
Differential regulation of chondrocyte metabolism by oncostatin M and interleukin-6.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2004;12(10):801-10.
2004: Annalisa Tancredi; Jean-Yves Reginster; Florence Schleich; Georges Pire; Philippe Maassen; Françoise Luyckx; Jean-Jacques Legros
Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers.
European journal of endocrinology / European Federation of Endocrine Societies 2004;151(3):355-60.
2004: Laszlo Tanko; Yu Z Bagger; Peter Alexandersen; Jean-Pierre Devogelaer; Jean-Yves Reginster; Rosalind Chick; Melvin Olson; Hakim Benmammar; Linda Mindeholm; Moïse Azria; Claus Christiansen
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(9):1531-8.
2004: Jean-Yves Reginster; Marie-Paule Lecart; Rita Deroisy; Christian Lousberg
Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Expert opinion on investigational drugs 2004;13(7):857-64.
2004: Florent Richy; Olivier Bruyere; Olivier Ethgen; Véronique Rabenda; G Bouvenot; M Audran; Gabriel Herrero-Beaumont; A Moore; R Eliakim; M Haim; Jean-Yves Reginster
Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach.
Annals of the rheumatic diseases 2004;63(7):759-66.
2004: Olivier Ethgen; Olivier Bruyère; Florent Richy; Charles Dardennes; Jean-Yves Reginster
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature.
The Journal of bone and joint surgery. American volume 2004;86-A(5):963-74.
2004: Eric Abadie; Dominique Ethgen; Bernard Avouac; Gilles Bouvenot; Jaime Branco; Olivier Bruyere; Gonzalo Calvo; Jean-Pierre Devogelaer; Renèe-Liliane Dreiser; Gabriel Herrero-Beaumont; Andre Kahan; Gottfried Kreutz; Andrea Laslop; Ernst-Martin Lemmel; George Nuki; L B A Van De Putte; Luc VanHaelst; Jean-Yves Reginster
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2004;12(4):263-8.
2004: Florent Richy; Olivier Ethgen; Olivier Bruyere; Jean-Yves Reginster
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2004;15(4):301-10.
2004: Olivier Ethgen; P Vanparijs; Sylvie Delhalle; S Rosant; Olivier Bruyère; Jean-Yves Reginster
Social support and health-related quality of life in hip and knee osteoarthritis.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2004;13(2):321-30.
2004: Somnath Sarkar; Jean-Yves Reginster; Gerald G Crans; Adolfo Diez-Perez; Karen V Pinette; Pierre D Delmas
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(3):394-401.
2004: Olivier Bruyere; Karel Pavelka; Lucio C Rovati; Rita Deroisy; Marta Olejarova; Jindriska Gatterova; Giampaolo Giacovelli; Jean-Yves Reginster
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies.
Menopause (New York, N.Y.) 2004;11(2):138-43.
2004: Jean-Yves Reginster
[Chondromodulation in 2003: dream or reality?].
Revue médicale de la Suisse romande 2004;124(2):85-7.
2004: Jean-Yves Reginster; S Sarkar; Brigitte Zegels; Yves Henrotin; Olivier Bruyere; D Agnusdei; Julien Collette
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Bone 2004;34(2):344-51.
2004: Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
The New England journal of medicine 2004;350(5):459-68.
2004: Yves Henrotin; Michelle A Deberg; J-E Dubuc; E Quettier; Stephan Christgau; Jean-Yves Reginster
Type II collagen peptides for measuring cartilage degradation.
Biorheology 2004;41(3-4):543-7.
2004: Florent Richy; Margaret L Gourlay; Joanne M Garrett; Laura C Hanson; Jean-Yves Reginster
Osteoporosis prevalence in men varies by the normative reference.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2004;7(2):127-33.
2004: Jean-Yves Reginster; Wafa Ben Sedrine; P Viethel; Marie-Christine Micheletti; thierry chevallier; M Audran
Validation of OSIRIS, a prescreening tool for the identification of women with an increased risk of osteoporosis.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004;18(1):3-8.
2004: Stephan Christgau; Yves Henrotin; Laszlo Tanko; Lucio C Rovati; Julien Collette; Olivier Bruyere; Rita Deroisy; Jean-Yves Reginster
Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate.
Clinical and experimental rheumatology 2004;22(1):36-42.
2004: Florent Richy; Margaret L Gourlay; Philip Ross; S S Sen; L Radican; F De Ceulaer; Wafa Ben Sedrine; Olivier Ethgen; Olivier Bruyere; Jean-Yves Reginster
Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium.
QJM : monthly journal of the Association of Physicians 2004;97(1):39-46.
2004: O Ethgen; Jean-Yves Reginster
Degenerative musculoskeletal disease.
Annals of the rheumatic diseases 2004;63(1):1-3.
2003: Olivier Bruyere; John Edwards; Jean-Yves Reginster
Fracture prevention in postmenopausal women.
Clinical evidence 2003;(10):1304-22.
2003: Jean-Pierre Devogelaer; Renèe-Liliane Dreiser; Eric Abadie; Bernard Avouac; G Bouvenot; J Carbonell Abello; J M Kaufman; Bart Koes; Andrea Laslop; Ernst-Martin Lemmel; Florent Richy; S Rozenberg; V Tavares; J P Valat; Jean-Yves Reginster
Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain.
Clinical and experimental rheumatology 2003;21(6):691-4.
2003: Olivier Ethgen; Annalisa Tancredi; Eric Lejeune; Angela Kvasz; Brigitte Zegels; Jean-Yves Reginster
Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC Index.
The Journal of rheumatology 2003;30(11):2452-9.
2003: Karel Pavelka; Olivier Bruyere; Lucio C Rovati; M Olejárova; Giampaolo Giacovelli; Jean-Yves Reginster
Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2003;11(10):730-7.
2003: Margaret L Gourlay; Florent Richy; Jean-Yves Reginster
Strategies for the prevention of hip fracture.
The American journal of medicine 2003;115(4):309-17.
2003: Jean-Yves Reginster; Olivier Bruyere; Marie-Paule Lecart; Yves Henrotin
Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis.
Current opinion in rheumatology 2003;15(5):651-5.
2003: Annie W C Kung; Andrew Y Y Ho; Wafa Ben Sedrine; Jean-Yves Reginster; Philip Ross
Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14(9):716-21.
2003: Jean-Yves Reginster; Dieter Felsenberg; Imre Pavo; Jan J Stepan; Juraj Payer; Heinrich Resch; Claus Glüer; Dieter Mühlenbacher; Deborah Quail; Henry Schmitt; Thomas Nickelsen
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14(9):741-9.
2003: Jean-Yves Reginster; Olivier Bruyere; Yves Henrotin
New perspectives in the management of osteoarthritis. structure modification: facts or fantasy?
The Journal of rheumatology. Supplement 2003;67():14-20.
2003: Yves Henrotin; Christelle Sanchez; Michelle A Deberg; Nathalie Piccardi; Georges Bernard Guillou; Philippe Msika; Jean-Yves Reginster
Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes.
The Journal of rheumatology 2003;30(8):1825-34.
2003: Florent Richy; Olivier Bruyere; Olivier Ethgen; Michel Cucherat; Yves Henrotin; Jean-Yves Reginster
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis.
Archives of internal medicine 2003;163(13):1514-22.
2003: Véronique Rabenda; Jacques Boniver; Jean-Yves Reginster
[Numerus clausus at the end of the third year of medical school].
Revue médicale de Liège 2003;58(7-8):508-14.
2003: Olivier Bruyere; John Edwards; Jean-Yves Reginster
Fracture prevention in postmenopausal women.
Clinical evidence 2003;(9):1186-202.
2003: Olivier Ethgen; Véronique Tellier; WB Sedrine; Jan De Maeseneer; Christiane Gosset; Jean-Yves Reginster
Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers?
Bone 2003;32(6):718-24.
2003: J Collette; P Viethel; M Dethor; thierry chevallier; Marie-Christine Micheletti; J M Foidart; Jean-Yves Reginster
[Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
Gynécologie, obstétrique & fertilité 2003;31(5):434-41.
2003: Olivier Bruyere; C Dardenne; Eric Lejeune; Brigitte Zegels; A Pahaut; Florent Richy; Laurence Seidel; Olivier Ethgen; Yves Henrotin; Jean-Yves Reginster
Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis.
Bone 2003;32(5):541-5.
2003: Olivier Bruyere; Julien Collette; Olivier Ethgen; Lucio C Rovati; Giampaolo Giacovelli; Yves Henrotin; Laurence Seidel; Jean-Yves Reginster
Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis.
The Journal of rheumatology 2003;30(5):1043-50.
2003: Florent Richy; Jean Bousquet; George E Ehrlich; Pierre J Meunier; Elliot Israel; Hirotoshi Morii; Jean-Pierre Devogelaer; Nicola Peel; Muriel Haim; Olivier Bruyere; Jean-Yves Reginster
Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14(3):179-90.
2003: Olivier Bruyere; Julien Collette; Pierre Delmas; Alain Rouillon; Christian Roux; Laurence Seidel; Florent Richy; Jean-Yves Reginster
Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women.
Maturitas 2003;44(4):259-65.
2003: Olivier Bruyère; Yves Henrotin; Aline Honoré; Lucio C Rovati; Laurence Seidel; Charles Dardenne; Jean-Yves Reginster
Impact of the joint space width measurement method on the design of knee osteoarthritis studies.
Aging clinical and experimental research 2003;15(2):136-41.
2003: Jean-Yves Reginster; MP Lecart; Nathalie Sarlet; V Halkin
[Prevention of hip fractures in the elderly: where are we in 2003?].
Revue médicale de Liège 2003;58(4):183-90.
2003: Olivier Ethgen; Florent Richy; Christiane Gosset; Linda Hanssens; Jean-Yves Reginster
[Prevention of frailty in the elderly: a demographic challenge].
Revue médicale de Liège 2003;58(4):175-82.
2003: Steven Boonen; Jean-Marc Kaufman; Jean-Yves Reginster; Jean-Pierre Devogelaer
Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14(2):110-5.
2003: Marianne Mathy-Hartert; G Martin; Philippe Devel; Ginette Deby-Dupont; Jean-Pierre Pujol; Jean-Yves Reginster; Yves Henrotin
Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2003;52(3):111-8.
2003: Jean-Yves Reginster; Rita Deroisy; Isabelle Jupsin
Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Drugs of today (Barcelona, Spain : 1998) 2003;39(2):89-101.
2003: Ole Helmer Sorensen; G M Crawford; H Mulder; D J Hosking; C Gennari; D Mellstrom; S Pack; D Wenderoth; C Cooper; Jean-Yves Reginster
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
Bone 2003;32(2):120-6.
2003: Christelle Sanchez; Marianne Mathy-Hartert; Michelle A Deberg; Herve Ficheux; Jean-Yves Reginster; Yves Henrotin
Effects of rhein on human articular chondrocytes in alginate beads.
Biochemical pharmacology 2003;65(3):377-88.
2003: H M Park; W Ben Sedrine; Jean-Yves Reginster; Philip Ross
Korean experience with the OSTA risk index for osteoporosis: a validation study.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2003;6(3):247-50.
2003: David J Hosking; Silvano Adami; Dieter Felsenberg; Jorge Cannata Andia; Matti Välimäki; Laurent Benhamou; Jean-Yves Reginster; Carol Yacik; Andrea Rybak-Feglin; Richard A Petruschke; Luna Zaru; Arthur C Santora
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Current medical research and opinion 2003;19(5):383-94.
2003: Jean-Yves Reginster; P J Meunier
Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14 Suppl 3():S56-65.
2003: Pierre J Meunier; Jean-Yves Reginster
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2003;14 Suppl 3():S66-76.
2003: Olivier Bruyere; A Honore; Olivier Ethgen; Lucio C Rovati; Giampaolo Giacovelli; Yves Henrotin; Laurence Seidel; Jean-Yves Reginster
Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2003;11(1):1-5.
2002: Olivier Bruyere; Jean-Yves Reginster; John Edwards
Fracture prevention in postmenopausal women.
Clinical evidence 2002;(8):1089-102.
2002: Jean-Yves Reginster; Rita Deroisy; M Dougados; Isabelle Jupsin; J Colette; Christian Roux
Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2002;13(12):925-31.
2002: Olivier Ethgen; Jean-Yves Reginster
[Quality of life assessment in clinical trials: a holistic approach to health].
Revue médicale de Liège 2002;57(11):695-700.
2002: Pierre D Delmas; Kristine E Ensrud; Jonathan D Adachi; Kristine D Harper; Somnath Sarkar; Carlo Gennari; Jean-Yves Reginster; Huibert A P Pols; Robert R Recker; Steven T Harris; Wentao Wu; Harry K Genant; Dennis M Black; Ana Munoz
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
The Journal of clinical endocrinology and metabolism 2002;87(8):3609-17.
2002: Marianne Mathy-Hartert; Ginette Deby-Dupont; Jean-Yves Reginster; N Ayache; Jean-Pierre Pujol; Yves Henrotin
Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2002;10(7):547-55.
2002: Wafa Ben Sedrine; Jean-Yves Reginster
Risk indices and osteoporosis screening: scope and limits.
Mayo Clinic proceedings. Mayo Clinic 2002;77(7):622-3.
2002: Olivier Bruyere; Jean-Yves Reginster
Fracture prevention in postmenopausal women.
Clinical evidence 2002;(7):979-82.
2002: WB Sedrine; thierry chevallier; Brigitte Zegels; Angela Kvasz; Marie-Christine Micheletti; B Gelas; Jean-Yves Reginster
Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2002;16(3):245-50.
2002: Olivier Ethgen; Kristijan Kahler; Sheldon X Kong; Jean-Yves Reginster; Frederick Wolfe
The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis.
The Journal of rheumatology 2002;29(6):1147-55.
2002: Wafa Ben Sedrine; P Broers; Jean-Pierre Devogelaer; Geneviève Depresseux; Jean-Marc Kaufman; Stefan Goemaere; Jean-Yves Reginster
Interest of a prescreening questionnaire to reduce the cost of bone densitometry.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2002;13(5):434-42.
2002: N Ayache; Karim Boumediene; Marianne Mathy-Hartert; Jean-Yves Reginster; Yves Henrotin; Jean-Pierre Pujol
Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2002;10(5):344-52.
2002: Pierre J Meunier; Daniel O Slosman; Pierre D Delmas; Jean-Luc Sebert; M L Brandi; Carlina Albanese; R Lorenc; Stig Pors-Nielsen; M C De Vernejoul; A Roces; Jean-Yves Reginster
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial.
The Journal of clinical endocrinology and metabolism 2002;87(5):2060-6.
2002: Jean-Yves Reginster
The prevalence and burden of arthritis.
Rheumatology (Oxford, England) 2002;41 Supp 1():3-6.
2002: Jean-Yves Reginster; N G Khaltaev
Introduction and WHO perspective on the global burden of musculoskeletal conditions.
Rheumatology (Oxford, England) 2002;41 Supp 1():1-2.
2002: Christelle Sanchez; Marguarida M Mateus; Marie-Paule Defresne; Jean-Michel Crielaard; Jean-Yves Reginster; Yves Henrotin
Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs.
The Journal of rheumatology 2002;29(4):772-82.
2002: Olof Johnell; Wim H Scheele; Yili Lu; Jean-Yves Reginster; Allan G Need; Ego Seeman
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
The Journal of clinical endocrinology and metabolism 2002;87(3):985-92.
2002: Rita Deroisy; Julien Collette; A Albert; Isabelle Jupsin; Jean-Yves Reginster
Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels.
Aging clinical and experimental research 2002;14(1):13-7.
2002: Jean-Yves Reginster; Brigitte Zegels; Eric Lejeune; Marie-Christine Micheletti; A Kvsaz; Laurence Seidel; Nathalie Sarlet
Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion.
Calcified tissue international 2002;70(2):78-82.
2002: Jean-Yves Reginster
Strontium ranelate in osteoporosis.
Current pharmaceutical design 2002;8(21):1907-16.
2002: Olivier Bruyere; Aline Honore; Lucio C Rovati; Giampaolo Giacovelli; Yves Henrotin; Laurence Seidel; Jean-Yves Reginster
Radiologic features poorly predict clinical outcomes in knee osteoarthritis.
Scandinavian journal of rheumatology 2002;31(1):13-6.
2002: Pierre D Delmas; Gonzalo Calvo; M Boers; Eric Abadie; Bernard Avouac; A Kahan; Jean-Marc Kaufman; Andrea Laslop; J F Lekkerkerker; P Nilsson; Barbara van Zwieten-Boot; Gottfried Kreutz; Jean-Yves Reginster
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2002;13(1):1-5.
2001: I Paul; A Bilge; F Bolly; J Boland; Jean-Yves Reginster
[Pilot study for the registration of acute myocardial infarction in the Liège area (Belgium)].
Revue d'épidémiologie et de santé publique 2001;49(5):423-9.
2001: Wafa Ben Sedrine; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Stefan Goemaere; Geneviève Depresseux; Brigitte Zegels; Rita Deroisy; Jean-Yves Reginster
Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium.
Bone 2001;29(4):374-80.
2001: Jean-Yves Reginster; Yves Henrotin; C Christiansen; E Gamwell-Henriksen; Julien Collette; Stephan Christgau
Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.
Calcified tissue international 2001;69(3):130-7.
2001: Yves Henrotin; Xavier de Leval; M Mathy-Hartet; Ange Mouithys-Mickalad; Ginette Deby-Dupont; Jean-Michel Dogné; Jacques Delarge; Jean-Yves Reginster
In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2001;50(8):391-9.
2001: Jean-Yves Reginster; I Paul; Yves Henrotin
[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?].
Revue médicale de Liège 2001;56(7):484-8.
2001: Yves Henrotin; Ginette Deby-Dupont; Jean-Yves Reginster
[Biochemical mediators of inflammation].
Revue médicale de Liège 2001;56(6):433-42.
2001: Robert M Neer; C D Arnaud; Jose R Zanchetta; Richard Prince; Gregory A Gaich; Jean-Yves Reginster; Anthony B Hodsman; Erik Fink Eriksen; Sophia Ish-Shalom; Harry K Genant; Ouhong Wang; Bruce H Mitlak
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
The New England journal of medicine 2001;344(19):1434-41.
2001: Eric Vignon; Patrick Garnero; P Delmas; Bernard Avouac; P Bettica; M Boers; E Ehrich; N MacKillop; L Rovati; U Serni; T Spector; Jean-Yves Reginster
Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2001;9(4):289-93.
2001: Jean-Yves Reginster; Yves Henrotin
[Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives].
Revue médicale de Liège 2001;56(3):135-9.
2001: Jean-Yves Reginster
Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
Clinical and experimental rheumatology 2001;19(2):121-2.
2001: Jean-Yves Reginster; Yves Henrotin
[Pharmacy clinics. How I treat...arthritis. First part: pathophysiologic recurrence and symptomatic treatment].
Revue médicale de Liège 2001;56(2):63-7.
2001: Jean-Yves Reginster; Brigitte Zegels; Eric Lejeune; Marie-Christine Micheletti; AN Taquet; A Albert
Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2001;15(1):56-62.
2001: Yves Henrotin; Alain Labasse; SX Zheng; P Galais; Y Tsouderos; Jean-Michel Crielaard; Jean-Yves Reginster
Strontium ranelate increases cartilage matrix formation.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2001;16(2):299-308.
2001: Jean-Yves Reginster; Rita Deroisy; Lucio C Rovati; Richard L Lee; Eric Lejeune; Olivier Bruyere; Giampaolo Giacovelli; Yves Henrotin; Jane E Dacre; C Gossett
Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.
Lancet 2001;357(9252):251-6.
2001: Jean-Yves Reginster; Pierre Gillet; Christiane Gosset
Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy.
Bulletin of the World Health Organization 2001;79(10):942-6.
2001: Jean-Yves Reginster; C Christiansen; Christian Roux; J Fechtenbaum; A Rouillon; K P Tou
Intermittent cyclic tiludronate in the treatment of osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2001;12(3):169-77.
2001: Véronique Tellier; Jan De Maeseneer; L De Prins; WB Sedrine; Christiane Gosset; Jean-Yves Reginster
Intensive and prolonged health promotion strategy may increase awareness of osteoporosis among postmenopausal women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2001;12(2):131-5.
2001: Brigitte Zegels; R Eastell; R G Russell; Dominique Ethgen; I Roumagnac; Julien Collette; Jean-Yves Reginster
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
Bone 2001;28(1):108-12.
2001: Wafa Ben Sedrine; L Radican; Jean-Yves Reginster
On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO Collaborating Center.
Rheumatology (Oxford, England) 2001;40(1):7-14.
2000: Jean-Yves Reginster; V Gillot; Olivier Bruyere; Yves Henrotin
Evidence of nutriceutical effectiveness in the treatment of osteoarthritis.
Current rheumatology reports 2000;2(6):472-7.
2000: Ange Mouithys-Mickalad; SX Zheng; Ginette Deby-Dupont; Carol Deby; M M Lamy; Jean-Yves Reginster; Yves Henrotin
In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR).
Free radical research 2000;33(5):607-21.
2000: Yves Henrotin; SX Zheng; Alain Labasse; GP Deby; Jean-Michel Crielaard; Jean-Yves Reginster
Modulation of human chondrocyte metabolism by recombinant human interferon.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2000;8(6):474-82.
2000: SX Zheng; Ange Mouithys-Mickalad; Ginette Deby-Dupont; Carol Deby; A P Maroulis; Alain Labasse; Maurice L Lamy; Jean-Michel Crielaard; Jean-Yves Reginster; Yves Henrotin
In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: effects on HRP- and luminol-dependent chemiluminescence produced by human chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2000;8(6):419-25.
2000: Jean-Marc Kaufman; Olof Johnell; Eric Abadie; S Adami; M Audran; Bernard Avouac; WB Sedrine; Gonzalo Calvo; Jean-Pierre Devogelaer; V Fuchs; Gottfried Kreutz; P Nilsson; H Pols; Johann D Ringe; L Van Haelst; Jean-Yves Reginster
Background for studies on the treatment of male osteoporosis: state of the art.
Annals of the rheumatic diseases 2000;59(10):765-72.
2000: Jean-Yves Reginster; Y Donazzolo; N Brion; R Lins
Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Climacteric : the journal of the International Menopause Society 2000;3(3):168-75.
2000: Jean-Yves Reginster; Olivier Bruyere; M Audran; Bernard Avouac; J J Body; G Bouvenot; M L Brandi; C Gennari; Jean-Marc Kaufman; Ernst-Martin Lemmel; Luc VanHaelst; G Weryha; Jean-Pierre Devogelaer
Do estrogens effectively prevent osteoporosis-related fractures? The Group for the Respect of Ethics and Excellence in Science.
Calcified tissue international 2000;67(3):191-4.
2000: J K Manzambi; Véronique Tellier; F Bertrand; A Albert; Jean-Yves Reginster; E H Van Balen
[The behavioral determinants for health centers in health districts of urban Africa: results of a survey of households in Kinshasa, Congo].
Tropical medicine & international health : TM & IH 2000;5(8):563-70.
2000: Jean-Marc Kaufman; J J Body; Steven Boonen; Jean-Pierre Devogelaer; Frank Raeman; S Rozenberg; Jean-Yves Reginster
[Involutional osteoporosis in women: therapeutic strategy. Recommendations of the Belgian Bone Club].
Revue médicale de Liège 2000;55(5):443-8.
2000: Jean-Yves Reginster; H W Minne; Ole Helmer Sorensen; M Hooper; Christian Roux; M L Brandi; B Lund; Dominique Ethgen; S Pack; I Roumagnac; R Eastell
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2000;11(1):83-91.
1999: Stefan Goemaere; Brigitte Zegels; K Toye; S Cremer; R Demuynck; M Daems; K Dobbelaere; WB Sedrine; A Albert; W Dewe; Jean-Marc Kaufman; Jean-Yves Reginster
Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors.
Calcified tissue international 1999;65(5):354-8.
1999: Jean-Yves Reginster; Rita Deroisy; I Paul; Michel Hansenne; marc ansseau
Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women.
Maturitas 1999;33(2):133-7.
1999: Jean-Yves Reginster; Donato Agnusdei; Carlo Gennari; P M Kicovic
Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1999;13(5):361-8.
1999: Jean-Yves Reginster; Cécile De Froidmont; MP Lecart; Nathalie Sarlet; J O Defraigne
Alphacalcidol in prevention of glucocorticoid-induced osteoporosis.
Calcified tissue international 1999;65(4):328-31.
1999: Jean-Marc Kaufman; J Compston; M A Audran; Bernard Avouac; Jean-Pierre Devogelaer; Ernst-Martin Lemmel; Luc VanHaelst; Jean-Yves Reginster
Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis.
Calcified tissue international 1999;65(1):4-7.
1999: Jean-Yves Reginster
Treatment of osteoporosis: where are we and where are we going to.
Morphologie : bulletin de l'Association des anatomistes 1999;83(261):41-5.
1999: Jean-Yves Reginster; Pierre Gillet; Wafa Ben Sedrine; G Brands; Olivier Ethgen; Cécile De Froidmont; Christiane Gosset
Direct costs of hip fractures in patients over 60 years of age in Belgium.
PharmacoEconomics 1999;15(5):507-14.
1999: Xavier de Leval; Jean-Michel Dogné; P Neven; Alain Labasse; Jacques Delarge; Jean-Yves Reginster; Yves Henrotin
Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.
Journal de pharmacie de Belgique 1999;54(3):89-90.
1999: Y Henroitin; Jean-Yves Reginster
In-vitro differences among nonsteroidal antiinflammatory drugs in their activities related to osteoarthritis pathophysiology.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 1999;7(3):355-7.
1999: Yves Henrotin; Jean-Yves Reginster
Anabolic events in osteoarthritis.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 1999;7(3):310-2.
1999: Jean-Yves Reginster; Jean-Pierre Devogelaer; Jean-Marc Kaufman; T Appelboom; Luc VanHaelst
[Postmenopausal osteoporosis in women].
Revue médicale de Liège 1999;54(4):335-40.
1999: Jean-Yves Reginster; Y Henrotin; Christiane Gosset
Promising new agents in osteoporosis.
Drugs in R&D 1999;1(3):195-201.
1999: Yves Henrotin; Alain Labasse; P E Simonis; SX Zheng; GP Deby; J P Famaey; Jean-Michel Crielaard; Jean-Yves Reginster
Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro.
Clinical and experimental rheumatology 1999;17(2):151-60.
1999: Jean-Yves Reginster; Jean-Pierre Devogelaer; Jean-Marc Kaufman; T Appelboom; Luc VanHaelst
[How to evaluate osteoporosis: bone densitometry and biochemical tests].
Revue médicale de Liège 1999;54(3):184-8.
1999: Jean-Yves Reginster; V Halkin; Y Henrotin; Christiane Gosset
Treatment of osteoporosis: role of bone-forming agents.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1999;9 Suppl 2():S91-6.
1999: Jean-Yves Reginster; Rita Deroisy; H Pirenne; I Frederick; W Dewe; A Albert; Julien Collette; SX Zheng; Christiane Gosset
High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: a plausible role of increased parathyroid hormone secretion.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1999;9(2):121-8.
1999: Jean-Yves Reginster; D Kuntz; W Verdickt; M Wouters; L Guillevin; C J Menkès; K Nielsen
Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1999;9(1):75-81.
1998: Jean-Yves Reginster; M Dethor; H Pirenne; W Dewe; A Albert
Reproducibility and diagnostic sensitivity of ultrasonometry of the phalanges to assess osteoporosis.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 1998;63(1):21-8.
1998: Yves Henrotin; SX Zheng; GP Deby; Alain Labasse; Jean-Michel Crielaard; Jean-Yves Reginster
Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes.
The Journal of rheumatology 1998;25(8):1595-601.
1998: Jean-Yves Reginster; L Meurmans; Brigitte Zegels; Lucio C Rovati; H W Minne; Giampaolo Giacovelli; AN Taquet; Ivo Setnikar; Julien Collette; Christiane Gosset
The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Annals of internal medicine 1998;129(1):1-8.
1998: Jean-Yves Reginster; AN Taquet; Christiane Gosset
Therapy for osteoporosis. Miscellaneous and experimental agents.
Endocrinology and metabolism clinics of North America 1998;27(2):453-63.
1998: Jean-Yves Reginster; Wafa Ben Sedrine; Christiane Gosset
[Bone-specific treatment design in the treatment of postmenopausal osteoporosis. Pharmaco-economic aspects].
Revue médicale de Liège 1998;53(5):290-3.
1998: John Stevenson; U Gaspard; Bernard Avouac; C Bricaire; Linda Cardozo; P Collins; Jean-Pierre Devogelaer; M Dören; C Gennari; Jean-Marc Kaufman; F Kuttenn; J D Ringe; C Scarafiotti; Luc VanHaelst; L Zichella; R Ziegler; Jean-Yves Reginster
Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Department of Urogynaecology, King's College Hospital, London.
Climacteric : the journal of the International Menopause Society 1998;1(1):12-7.
1998: Jean-Yves Reginster; I Frederick; Rita Deroisy; W Dewe; AN Taquet; A Albert; Julien Collette; H Pirenne; SX Zheng; Christiane Gosset
Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1998;8(4):390-2.
1998: Pierre J Meunier; Jean-Luc Sebert; Jean-Yves Reginster; D Briancon; T Appelboom; P Netter; G Loeb; A Rouillon; S Barry; JC Evreux; B Avouac; X Marchandise
Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1998;8(1):4-12.
1998: Yves Henrotin; Alain Labasse; J M Jaspar; DD De Groote; SX Zheng; G B Guillou; Jean-Yves Reginster
Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes.
Clinical rheumatology 1998;17(1):31-9.
1997: Jean-Marc Kaufman; Jean-Pierre Devogelaer; Frank Raeman; S Rozenberg; J J Body; René Westhovens; Jean-Yves Reginster
Prevention and treatment of postmenopausal osteoporosis. National Consensus of the "Belgian Bone Club", November 1996.
Clinical rheumatology 1997;16(4):343-5.
1997: Jean-Yves Reginster; A Albert; Rita Deroisy; J Colette; B Vrijens; C Blacker; N Brion; F Caulin; C Mayolle; A Regnard; R Scholler; P Franchimont
Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Maturitas 1997;27(2):179-86.
1997: Rita Deroisy; M Zartarian; L Meurmans; N Nelissenne; Marie-Christine Micheletti; A Albert; Jean-Yves Reginster
Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers.
Clinical rheumatology 1997;16(3):249-53.
1997: Jean-Yves Reginster
[How I treat...senile osteoporosis].
Revue médicale de Liège 1997;52(4):267-9.
1997: V Halkin; N Francotte-Lempereur; A Debrun; Jean-Yves Reginster
[Clinical case of the month. Osteoporosis and beta-thalassemia].
Revue médicale de Liège 1997;52(3):138-41.
1997: Jean-Yves Reginster; Rita Deroisy; Julien Collette; A Albert; Brigitte Zegels
Prediction of bone loss rate in healthy postmenopausal women.
Calcified tissue international 1997;60(3):261-4.
1997: Jean-Yves Reginster; AN Taquet; G Fraikin; Christiane Gosset; Brigitte Zegels
Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1997;7 Suppl 3():S163-8.
1997: B Clemmesen; Pernille Ravn; Brigitte Zegels; AN Taquet; Claus Christiansen; Jean-Yves Reginster
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1997;7(5):488-95.
1997: Jean-Yves Reginster; L Bufalino; C Christiansen; Jean-Pierre Devogelaer; Carlo Gennari; B J Riis; Christian Roux
Design for an ipriflavone multicenter European fracture study.
Calcified tissue international 1997;61 Suppl 1():S28-32.
1997: Jean-Yves Reginster
[Calcitonin and bone aging].
Pathologie-biologie 1997;45(1):52-6.
1997: Jean-Yves Reginster; Rita Deroisy; Brigitte Zegels; D Denis; G Reginster-Haneuse; P Dirick; P Taziaux; A Albert; C Boelen
[Prevention of osteoporosis in Liège. Evaluation of a trial between general practitioners and university specialists (1)].
Revue médicale de Liège 1997;52(1):31-6.
1997: SX Zheng; Y Vrindts; M Lopez; DD De Groote; P F Zangerle; Julien Collette; Nathalie Franchimont; Vincent Geenen; A Albert; Jean-Yves Reginster
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis.
Maturitas 1997;26(1):63-71.
1997: Jean-Yves Reginster
Miscellaneous and experimental agents.
The American journal of the medical sciences 1997;313(1):33-40.
1996: Jean-Yves Reginster; M Zartarian; J C Colau
[Influence of nomegestrol acetate on the improvement of the quality of life induced by estrogen therapy in menopausal women].
Contraception, fertilité, sexualité (1992) 1996;24(11):847-51.
1996: Jean-Yves Reginster
[Prevention of postmenopausal osteoporosis: estrogens and nonhormonal drugs].
Revue médicale de Liège 1996;51(10):649-53.
1996: Yves Henrotin; DD De Groote; Alain Labasse; S E Gaspar; SX Zheng; Vincent Geenen; Jean-Yves Reginster
Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 1996;4(3):163-73.
1996: Jean-Yves Reginster; M Distel; E Bluhmki
A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis.
British journal of rheumatology 1996;35 Suppl 1():17-21.
1996: C Bassleer; J M Jaspar; Jean-Yves Reginster; V Geenen
[Effects of interleukin-1 on human chondrocytes cultured in aggregates].
La Revue du praticien 1996;46(6 Spec No):S31-S34.
1996: C T Bassleer; P P Franchimont; Yves Henrotin; N M Franchimont; Vincent Geenen; Jean-Yves Reginster
Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 1996;4(1):1-8.
1996: Jean-Yves Reginster
[Evaluation of the preventive role of estro-progestogens and non-hormonal therapies in postmenopausal osteoporosis].
Journal de gynécologie, obstétrique et biologie de la reproduction 1996;25(7):677-83.
1995: Jean-Yves Reginster; M P Lecart
Efficacy and safety of drugs for Paget's disease of bone.
Bone 1995;17(5 Suppl):485S-488S.
1995: Jean-Yves Reginster
The role of bisphosphonates in the prevention and treatment of osteoporosis.
Clinical rheumatology 1995;14 Suppl 3():22-5.
1995: Jean-Yves Reginster; I Jupsin; Rita Deroisy; I Biquet; Nathalie Franchimont; P Franchimont
Prevention of postmenopausal bone loss by rectal calcitonin.
Calcified tissue international 1995;56(6):539-42.
1995: Jean-Yves Reginster
[Calcium and skeleton: physiological basis of prevention].
Revue médicale de Liège 1995;50(6):244-8.
1995: Jean-Yves Reginster; Rita Deroisy; M P Lecart; N Sarlet; Brigitte Zegels; I Jupsin; M de Longueville; P Franchimont
A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
The American journal of medicine 1995;98(5):452-8.
1995: Jean-Yves Reginster; Rita Deroisy; Brigitte Zegels; I Jupsin; A Albert; P Franchimont
Long-term performance in vitro and in vivo of dual-energy X-ray absorptiometry.
Clinical rheumatology 1995;14(2):180-6.
1995: Jean-Yves Reginster; C Janssen; Rita Deroisy; Brigitte Zegels; A Albert; P Franchimont
Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females.
Clinical rheumatology 1995;14(1):68-75.
1995: Jean-Yves Reginster
Treatment of bone in elderly subjects: calcium, vitamin D, fluor, bisphosphonates, calcitonin.
Hormone research 1995;43(1-3):83-8.
1994: Jean-Yves Reginster; Rita Deroisy; P Franchimont
[Treatment of osteoporosis: current data and prospects].
Revue du rhumatisme (Ed. française : 1993) 1994;61(10 Pt 2):155S-164S.
1994: Jean-Yves Reginster; L Meurmans; Rita Deroisy; I Jupsin; I Biquet; A Albert; P Franchimont
A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
European journal of clinical investigation 1994;24(8):565-9.
1994: Jean-Yves Reginster; R Treves; J C Renier; B Amor; J Sany; D Ethgen; C Picot; P Franchimont
Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(5):615-9.
1994: Jean-Yves Reginster
[Calcitonin in the treatment and prevention of osteoporosis].
Revue médicale de Liège 1994;49(5):253-9.
1994: Jean-Yves Reginster
[Prevention of postmenopausal osteoporosis in case of contraindications of estrogens].
Revue médicale de Liège 1994;49(4):194-8.
1994: Jean-Yves Reginster; D Denis; Rita Deroisy; M P Lecart; M De Longueville; Brigitte Zegels; N Sarlet; P Noirfalisse; P Franchimont
Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(1):69-73.
1993: Jean-Yves Reginster
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
Bone and mineral 1993;23(3):223-32.
1993: Jean-Yves Reginster
Calcitonin for prevention and treatment of osteoporosis.
The American journal of medicine 1993;95(5A):44S-47S.
1993: Jean-Yves Reginster; D Denis; V Bartsch; Rita Deroisy; Brigitte Zegels; P Franchimont
Acute biochemical variations induced by four different calcium salts in healthy male volunteers.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1993;3(5):271-5.
1993: Jean-Yves Reginster; S Gaspar; Rita Deroisy; Brigitte Zegels; P Franchimont
Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1993;3(5):261-4.
1993: Jean-Yves Reginster; Claus Christiansen; B Dequinze; Rita Deroisy; Ulysse J Gaspard; AN Taquet; P Franchimont
Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause.
Calcified tissue international 1993;53(1):13-6.
1993: Jean-Yves Reginster
Calcitonins: newer routes of delivery.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1993;3 Suppl 2():S3-6; discussion S6-7.
1993: Jean-Yves Reginster; M P Lecart; Rita Deroisy; D Ethgen; Brigitte Zegels; P Franchimont
Paget's disease of bone treated with a five day course of oral tiludronate.
Annals of the rheumatic diseases 1993;52(1):54-7.
1993: Jean-Yves Reginster; P Franchimont
Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
European journal of rheumatology and inflammation 1993;12(4):38-46.
1992: Jean-Yves Reginster; N Sarlet; Rita Deroisy; A Albert; Ulysse J Gaspard; P Franchimont
Minimal levels of serum estradiol prevent postmenopausal bone loss.
Calcified tissue international 1992;51(5):340-3.
1992: Jean-Yves Reginster; F Colson; G Morlock; B Combe; D Ethgen; Piet Geusens
Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
Arthritis and rheumatism 1992;35(8):967-74.
1992: Jean-Yves Reginster; M Azria; S Gaspar; M Bleicher; Nathalie Franchimont; M Behhar; A Albert; P Franchimont
Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.
Calcified tissue international 1992;50(6):518-20.
1992: Jean-Yves Reginster; Rita Deroisy; M Bruwier; P Franchimont
Calcitonin metabolism in senile (type II) osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 1992;2(3):141-5.
1992: Jean-Yves Reginster; Rita Deroisy; M A Fontaine; P Franchimont
Influence of estrogen replacement therapy on endogenous calcitonin production rates.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1992;6(1):65-71.
1992: Jean-Yves Reginster; A M Jeugmans-Huynen; M Wouters; N Sarlet; H D McIntyre; P Franchimont
The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
British journal of rheumatology 1992;31(1):35-9.
1992: Jean-Yves Reginster
Management of high turnover osteoporosis with calcitonin.
Bone 1992;13 Suppl 2():S37-40.
1992: Jean-Yves Reginster
Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
Bone 1992;13(5):351-4.
1991: Jean-Yves Reginster
Effect of calcitonin on bone mass and fracture rates.
The American journal of medicine 1991;91(5B):19S-22S.
1991: F Wang; P de Marneffe; Jean-Yves Reginster; Jean-Michel Crielaard; P Franchimont
[Current aspects in medicine of the locomotor system. Urticarial vasculitis: apropos of a case].
Revue médicale de Liège 1991;46(6):336-42.
1990: Jean-Yves Reginster; D Denis; Rita Deroisy; A Albert; N Sarlet; Julien Collette; P Franchimont
Dual photon absorptiometry of lumbar spine in west European (Belgian) postmenopausal females: normal range and fracture threshold.
Clinical rheumatology 1990;9(2):220-4.
1990: Jean-Yves Reginster; C Gennari; C Mautalen; Rita Deroisy; D Denis; M P Lecart; J L Vandalem; Julien Collette; P Franchimont
Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone.
Scandinavian journal of rheumatology 1990;19(1):83-6.
1990: Jean-Yves Reginster; Rita Deroisy; M P Lecart; N Sarlet; M A Fontaine; A Albert; P Franchimont
Calcitonin and postmenopausal bone loss.
Experimental gerontology 1990;25(3-4):349-56.
1989: Jean-Yves Reginster; M P Lecart; Rita Deroisy; N Sarlet; D Denis; D Ethgen; Julien Collette; P Franchimont
Prevention of postmenopausal bone loss by tiludronate.
Lancet 1989;2(8678-8679):1469-71.
1989: Jean-Yves Reginster; S Almer; S Gaspar; A Albert; Rita Deroisy; P Franchimont
[Hypocalcemia induced in patients with Paget's disease by nasal salmon calcitonin. Effects of anti-calcitonin salmine antibodies].
Revue du rhumatisme et des maladies ostéo-articulaires 1989;56(7):563-7.
1989: Jean-Yves Reginster; M P Lecart; M Fontaine; Rita Deroisy; P Franchimont
[Corticosteroids and bone tissue].
Revue médicale de Liège 1989;44(10):365-73.
1989: Jean-Yves Reginster; Piet Geusens; Jos Nijs; D Denis; P Franchimont; J Dequeker
In vivo long-term precision of spinal bone mass measurement by dual photon absorptiometry.
Bone and mineral 1989;6(2):225-9.
1989: Jean-Yves Reginster; Rita Deroisy; D Denis; M P Lecart; P Franchimont
Salmon calcitonin: state of the art in prevention of postmenopausal bone loss?
Acta Belgica. Medica physica : organe officiel de la Société royale belge de médecine physique et de réhabilitation 1989;12(2):41-6.
1989: Jean-Yves Reginster; Rita Deroisy; M P Lecart; P Franchimont
(Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease.
Acta Belgica. Medica physica : organe officiel de la Société royale belge de médecine physique et de réhabilitation 1989;12(2):47-52.
1989: Jean-Yves Reginster; Rita Deroisy; A Albert; D Denis; M P Lecart; Julien Collette; P Franchimont
Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.
The Journal of clinical investigation 1989;83(3):1073-7.
1989: Yves Henrotin; C Bassleer; Jean-Yves Reginster; P Franchimont
Effects of etodolac on human chondrocytes cultivated in three dimensional culture.
Clinical rheumatology 1989;8 Suppl 1():36-42.
1989: Jean-Yves Reginster; N Sarlet; Rita Deroisy; D Denis; M P Lecart; P Franchimont
[Comparison of the osteoprotective effects of orally administered equine conjugated estrogens and percutaneous 17 beta-estradiol].
Revue médicale de Liège 1989;44(2):55-60.
1989: D Denis; M P Lecart; Rita Deroisy; A M Jeugmans-Huynen; A Albert; Jean-Yves Reginster; P Franchimont
[A years' treatment of Paget's disease of bone using salmon calcitonin via nasal spray].
Revue médicale de Liège 1989;44(1):23-7.
1989: P Franchimont; D Urbain-Choffray; P Lambelin; M A Fontaine; G Frangin; Jean-Yves Reginster
Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women.
Acta endocrinologica 1989;120(1):121-8.
1989: Jean-Yves Reginster; L Strause; Rita Deroisy; M P Lecart; P Saltman; P Franchimont
Preliminary report of decreased serum magnesium in postmenopausal osteoporosis.
Magnesium 1989;8(2):106-9.
1988: M P Lecart; A M Jeugmans-Huynen; A Albert; D Denis; Rita Deroisy; M A Fontaine; Julien Collette; Jean-Yves Reginster; P Franchimont
[Biological and clinical effects of a new diphosphonate (chloro-4-phenyl) thiomethylene-diphosphonate in Paget's disease of bone].
Revue médicale de Liège 1988;43(24):799-806.
1988: M P Lecart; D Denis; Rita Deroisy; Jean-Yves Reginster; P Franchimont
[Paget's disease 100 years after Sir Paget].
Revue médicale de Liège 1988;43(23):765-83.
1988: Jean-Yves Reginster; Rita Deroisy; D Denis; M P Lecart; N Sarlet; P Franchimont
Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1988;2(3):195-204.
1988: Jean-Yves Reginster; A M Jeugmans-Huynen; A Albert; D Denis; P Franchimont
One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1988;3(3):249-52.
1988: Jean-Yves Reginster; D Denis; A Albert; S Gaspar; G Heynen; Rita Deroisy; P Franchimont
Influence of the nature of calcium salts on serum calcium, phosphorus, calcitonin, growth hormone, and somatomedin C.
Research in experimental medicine. Zeitschrift für die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 1988;188(2):131-7.
1988: Jean-Yves Reginster; A M Jeugmans-Huynen; A Albert; D Denis; Rita Deroisy; M P Lecart; M A Fontaine; Julien Collette; P Franchimont
Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone.
Bone 1988;9(6):349-54.
1987: Jean-Yves Reginster; D Denis; A Albert; Rita Deroisy; M P Lecart; M A Fontaine; P Lambelin; P Franchimont
1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
Lancet 1987;2(8574):1481-3.
1987: Jean-Yves Reginster; D Denis; A Albert; P Franchimont
Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects.
Bone and mineral 1987;2(2):133-40.
1985: Jean-Yves Reginster; J M Crielaard; C Bassleer; P Gysen; M Bastings; P Franchimont
[Treatment of primary patellar chondromalacia using a combination of quadriceps rehabilitation and infrared laser irradiation].
Acta Belgica. Medica physica : organe officiel de la Société royale belge de médecine physique et de réhabilitation 1985;8(4):193-4.
1985: Jean-Yves Reginster; P Gysen; M Malaise; P Franchimont
[Changes in articular proteoglycans in treatment with tiaprofenic acid].
Revue médicale de Liège 1985;40(17):596-9.
1983: Jean-Yves Reginster; C Desaive; Julien Collette; P F Zangerle; P Franchimont
[Monitoring of rectocolic cancers treated surgically: practical application of carcino-embryonic antigen].
Revue médicale de Liège 1983;38(13-14):581-5.